

GENERAL MEETING OF APRIL 30, 2021

WRITTEN QUESTION

Written questions may be submitted to the Company, pursuant to the rules established by law, with respect to any General Meeting. In conformity with the legislation in force, an answer is deemed to have been given to a written question provided it has been displayed on the Company's website.

On April 28, 2021 the Board received the following question from Mrs. Jacquelyn VERALDI:

“Trinity College Cambridge has reviewed its investments with a view to antimicrobial resistance, which poses global health risks and therefore systemic risks for long-term investors. Sanofi has committed to supporting various AMR objectives and initiatives, yet in the Access to Medicine Foundation’s 2020 AMR Benchmark Report received the worst overall performance score of all the assessed large research-based pharmaceutical companies, performing particularly poorly on R&D indicators.

We note that Sanofi has not joined the AMR Action Fund, a coalition of more than 20 health companies that are investing over \$1 billion to bring two to four new antibiotics to market this decade.

Will Sanofi become a contributing member of the AMR Action Fund? If not, will Sanofi meet with representatives of Trinity College to discuss what actions it is taking to address the funding gap in the research and development of novel antibiotics?”

Response to the written question:

“As a leading pharmaceutical company, Sanofi participates in the fight against antimicrobial resistance. Sanofi encourages the collaboration with third parties like regulators, marketers, industry peers, international bodies or national governments, to address all the aspects of this issue. As a signatory of the Industry Roadmap for Progress on Combating AMR and as a member of the AMR Industry Alliance, we support the WHO’s Global Action Plan on AMR, as well as the new AMR & Vaccines Roadmap under development. Sanofi’s approach to combating AMR resistance is articulated around the following priorities:

- *Engaging in research and development to limit or prevent AMR: Sanofi continues to invest in the development of new antibacterial medicines, as well as in AMR-relevant vaccines.*
- *Preventing pharmaceuticals from entering the environment: Sanofi is committed to minimize the potential environmental impacts, including the emergence of AMR, of our medicines through its Planet Mobilization Program, 20 a strategic approach that covers the entire lifecycle of our medicines.*

- *Enabling appropriate patient access to antimicrobials and vaccines: Sanofi supports efforts to broaden vaccine coverage to prevent infections and help optimize the use of antimicrobials. Sanofi also strives to increase access to our antimicrobial medicines for the patients who need them.*
- *Preserving medical value of current antimicrobials through appropriate use and disposal: Sanofi engages in initiatives to encourage the appropriate use and disposal of medicines, in particular by promoting responsible behavior and sharing best practices among healthcare professionals and patients.*

We are also participating in the 2021 AMR Benchmark organized by the ATM Foundation.

To find out more about our AMR commitments and actions, please review our AMR factsheet, updated in 2021, available here:

<https://www.sanofi.com/-/media/Project/One-Sanofi-Web/Websites/Global/Sanofi-COM/Home/en/our-responsibility/docs/documents-center/factsheets/AntimicrobialResistanceAMR.pdf?la=en.>

* * *